cas 1299607-55-8|| where to buy tert-Butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

Nombre del producto:tert-Butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

IUPAC Name:tert-butyl 5-bromo-1H-pyrazolo[3,4-b]pyridine-1-carboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM151955-250mg	in stock	ŵȡ
CM151955-1g	in stock	ƛƥũ
CM151955-5g	in stock	Ȑƿƥ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1299607-55-8 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :1299607-55-8; Fórmula molecular:C11H12BrN3O2; Punto de fusión:-; Código de sonrisas:O=C(N1N=CC2=CC(Br)=CN=C21)OC(C)(C)C; Densidad:

: Número de catálogo:CM151955; Peso molecular:298.14; Punto de ebullición:; Nº Mdl:MFCD18803503; Almacenamiento:

: Pyrazolopyridines; Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

: Olverembatinib; Ascentage Pharma announced that updated results from three studies of olverembatinib, have been released in posters at the 2024 European Hematology Association Hybrid Congress, taking place in Madrid, Spain.
Olverembatinib (HQP1351) is an oral, third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by Ascentage Pharma for the treatment of chronic myeloid leukaemia (CML), acute myeloid leukaemia, acute lymphoblastic leukaemia (ALL) and solid tumours, including gastrointestinal stromal tumours (GIST). Olverembatinib is an ATP binding-site inhibitor of wild type BCR-ABL1 kinase and a broad spectrum of BCR-ABL1 mutants, including mutant T315I, which confers resistance against all first- and second-generation TKIs.